

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

<i>In re</i> Application	)	
	)	Examiner: NATARAJAN, MEERA
First Inventor: Xiangbin Wang	)	
	)	Group Art Unit: 3643
Application No.: 10/594,908	)	
	)	Confirmation No.: 3643
Filed: January 08, 2009	)	
	)	Customer No. 88993
Title: GENE ENGINEERING RECOMBINANT	)	
ANTI-CEA, ANTI-CD3, AND ANTI-CD28	)	
SINGLE-CHAIN TRI-SPECIFIC ANTIBODY	)	
<hr style="border: 1px solid black;"/>		

**Commissioner for Patents**  
P. O. Box 1450  
Alexandria, VA 22313-1450

**ELECTRONICALLY FILED**

**RESPONSE TO RESTRICTION REQUIREMENT**

In response to the Restriction Requirement dated October 27, 2010, Applicants hereby elect Group I for examination, which corresponds to Claims 21-33. The election is made without traverse. In addition, Applicants hereby elect the following species for examination: the single chain tri-specific antibody of SEQ ID NO: 4. Claims 21-33 encompass the elected species. Applicants expressly reserve the rights to pursue any non-elected claims in one or more divisional applications.

Applicants believe no official fees are due to accompany this submission. The Director is, however, authorized to charge any required fees, or to make any refund of an overpayment, to Deposit Account No. 50-4969.

Applicants submit that Claims 21-33 are now in proper condition for allowance, and requests the issuance of a Notice of Allowance at the Examiner's earliest convenience.